![](https://cdn.sanity.io/images/0vv8moc6/onclive/1518d2eae3a1b3b514c8b6648e7875c79f94d469-1667x1667.jpg?fit=crop&auto=format)
2024 FDA Approvals in Breast, Gynecologic, and Other Solid Tumors Represent Key Steps Forward
The first ever tumor-infiltrating lymphocyte (TIL) therapy to receive the go-ahead from the FDA, lifileucel (Amtagvi), gained an indication for patients with melanoma in 2024, marking an important milestone in a year with many. There were more than 65 …